Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
InMed Pharmaceuticals Inc. (INM)
|
Add to portfolio |
|
|
|
| Price: |
$1.36
| | Metrics |
| OS: |
3.33
|
M
| |
|
|
| Market cap: |
$4.53
|
M
| |
|
|
|
Net cash:
|
$8.58
|
M
| |
$2.58
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Jun-30-23 | Jun-30-22 | Jun-30-21 | Jun-30-20 | Jun-30-19 | Jun-30-18 |
| Revenues | 5.5 | 1.1 | 1.9 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 405.0% | -42.8% | | | | |
| Cost of goods sold | 2.4 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 3.1 | 0.5 | 1.9 | 0.0 | 0.0 | 0.0 |
| Gross margin | 55.9% | 49.9% | 100.0% | | | |
| Research and development | 3.7 | 7.3 | 5.3 | 5.8 | | |
| General and administrative | 6.2 | 7.2 | 4.5 | 3.2 | 4,296.5 | 6.1 |
| EBITA | -7.8 | -15.2 | -9.7 | -8.9 | -9,214.6 | -8.0 |
| EBITA margin | -141.7% | -1397.4% | -507.5% | | | |
| Amortization of intangibles | | | 0.1 | 0.1 | | |
| EBIT | -7.8 | -15.2 | -9.8 | -9.0 | -9,214.6 | -8.0 |
| EBIT margin | -141.7% | -1397.4% | -512.8% | | | |
| Pre-tax income | -7.9 | -18.6 | -10.2 | -8.9 | -9,248.5 | -8.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -7.9 | -18.6 | -10.2 | -8.9 | -9,248.5 | -8.0 |
| Net margin | -144.5% | -1707.3% | -535.9% | | | |
| |
| Diluted EPS | ($3.25) | ($33.17) | ($37.96) | ($1.71) | ($1,781.27) | ($1.86) |
| Shares outstanding (diluted) | 2.4 | 0.6 | 0.3 | 5.2 | 5.2 | 4.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|